CN101123878A - 氨基酸前药 - Google Patents

氨基酸前药 Download PDF

Info

Publication number
CN101123878A
CN101123878A CNA2004800282229A CN200480028222A CN101123878A CN 101123878 A CN101123878 A CN 101123878A CN A2004800282229 A CNA2004800282229 A CN A2004800282229A CN 200480028222 A CN200480028222 A CN 200480028222A CN 101123878 A CN101123878 A CN 101123878A
Authority
CN
China
Prior art keywords
compound
amino acid
hydroxyproline
patient
product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800282229A
Other languages
English (en)
Chinese (zh)
Inventor
V·拉维·詹德兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Signature R&D Holdings LLC
Original Assignee
Signature R&D Holdings LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signature R&D Holdings LLC filed Critical Signature R&D Holdings LLC
Publication of CN101123878A publication Critical patent/CN101123878A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CNA2004800282229A 2003-07-29 2004-07-29 氨基酸前药 Pending CN101123878A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49133103P 2003-07-29 2003-07-29
US60/491,331 2003-07-29

Publications (1)

Publication Number Publication Date
CN101123878A true CN101123878A (zh) 2008-02-13

Family

ID=34590076

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800282229A Pending CN101123878A (zh) 2003-07-29 2004-07-29 氨基酸前药

Country Status (11)

Country Link
EP (1) EP1660017A4 (https=)
JP (2) JP2007510621A (https=)
KR (3) KR20130081319A (https=)
CN (1) CN101123878A (https=)
AU (1) AU2004289174B2 (https=)
CA (1) CA2534342C (https=)
IL (1) IL173382A0 (https=)
NZ (3) NZ601780A (https=)
SG (2) SG178721A1 (https=)
WO (1) WO2005046575A2 (https=)
ZA (1) ZA200600660B (https=)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102924398A (zh) * 2012-11-22 2013-02-13 安徽贝克生物制药有限公司 用于除去依非韦伦对应异构体的方法
CN103263405A (zh) * 2013-05-08 2013-08-28 南京医科大学 用于治疗糖尿病的药物组合物及其应用
CN103360240A (zh) * 2013-07-23 2013-10-23 西安新通药物研究有限公司 一种高纯度非诺贝酸的制备方法
CN103880754A (zh) * 2012-12-21 2014-06-25 西藏海思科药业集团股份有限公司 一种丙泊酚碱性氨基酸酯盐
CN103951557A (zh) * 2014-04-22 2014-07-30 徐州工业职业技术学院 一种以无机碱为催化剂制备非诺贝特酸的方法
CN104628554A (zh) * 2015-02-09 2015-05-20 徐州工程学院 一种非诺贝特酸晶型及其制备方法
CN105037180A (zh) * 2015-04-19 2015-11-11 安徽省逸欣铭医药科技有限公司 一种双重作用的中枢性镇痛新化合物、制备方法及用途
CN106146444A (zh) * 2015-04-03 2016-11-23 米文君 一种新的化合物及其用途
CN106316921A (zh) * 2016-08-19 2017-01-11 河南东泰制药有限公司 一种阿西美辛的制备方法
WO2017193562A1 (zh) * 2016-05-10 2017-11-16 浙江海正药业股份有限公司 水溶性雷帕霉素类衍生物
CN108299219A (zh) * 2018-02-11 2018-07-20 中国农业大学 O-酰基化丝氨酸衍生物及其制备方法与应用
CN116041259A (zh) * 2023-01-13 2023-05-02 武汉科技大学 一种羟氯喹的衍生物及其制备方法
CN117247327A (zh) * 2023-10-13 2023-12-19 深圳市护家科技有限公司 补骨脂酚衍生物及其盐的制备方法和应用
CN119954651A (zh) * 2023-11-07 2025-05-09 深圳市护家科技有限公司 抗光老化护肤品、耐氧化抗衰老化合物及用途

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1603512A2 (en) 2003-03-17 2005-12-14 Albany Molecular Research, Inc. Novel cyclosporins
CN101123878A (zh) * 2003-07-29 2008-02-13 信号研发控股有限责任公司 氨基酸前药
US7589233B2 (en) 2003-07-29 2009-09-15 Signature R&D Holdings, Llc L-Threonine derivatives of high therapeutic index
US8173840B2 (en) 2003-07-29 2012-05-08 Signature R&D Holdings, Llc Compounds with high therapeutic index
JP2007517056A (ja) 2003-12-29 2007-06-28 セプラコア インコーポレーテッド ピロール及びピラゾールｄａａｏ阻害剤
WO2005066214A1 (ja) * 2004-01-07 2005-07-21 Seikagaku Corporation ヒアルロン酸誘導体及びそれを含む薬剤
WO2006017351A1 (en) 2004-07-12 2006-02-16 Xenoport, Inc. Prodrugs of propofol, compositions and uses thereof
US7378391B2 (en) 2004-09-29 2008-05-27 Amr Technology, Inc. Cyclosporin alkyne analogues and their pharmaceutical uses
WO2006039164A2 (en) 2004-09-29 2006-04-13 Amr Technology, Inc. Novel cyclosporin analogues and their pharmaceutical uses
WO2006041631A2 (en) 2004-10-06 2006-04-20 Amr Technology, Inc. Novel cyclosporin alkynes and their utility as pharmaceutical agents
BRPI0610368A8 (pt) * 2005-05-05 2015-09-08 Glaxosmithkline Ip Dev Ltd Modulação de enzima e de receptor
JP5713535B2 (ja) * 2005-11-11 2015-05-07 チャンドラン, ブイ., ラビChandran, V., Ravi 血小板凝集低下用薬学的組成物、血小板凝集低下用栄養組成物、および血小板凝集低下用食品又は飲料あるいは水性液体
US20070203111A1 (en) 2006-01-06 2007-08-30 Sepracor Inc. Cycloalkylamines as monoamine reuptake inhibitors
NZ569608A (en) 2006-01-06 2011-09-30 Sepracor Inc Tetralone-based monoamine reuptake inhibitors
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
CN101421228B (zh) 2006-03-31 2014-05-21 塞普拉柯公司 手性酰胺和胺的制备
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
JP2009542701A (ja) * 2006-07-06 2009-12-03 サイトビア インコーポレイティッド カスパーゼの活性化因子およびアポトーシスの誘導因子としてのならびに抗血管剤としての置換された４−アリール−クロメンおよびその使用法
CN1907954B (zh) * 2006-08-16 2011-11-23 重庆医科大学医药研究所 麻醉药2,6-二异丙基苯酚的水溶性衍生物及其制备方法
US8962825B2 (en) 2006-10-30 2015-02-24 Glaxosmithkline Intellectual Property Development Limited Hydroxamates as inhibitors of histone deacetylase
US7902252B2 (en) 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
CA2688493C (en) 2007-05-31 2016-04-19 Sepracor Inc. Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
WO2008157537A2 (en) * 2007-06-19 2008-12-24 Ironwood Pharmaceuticals, Inc Compositions and methods of use for treating or preventing lipid related disorders
US8778953B2 (en) 2008-02-29 2014-07-15 Chroma Therapeutics Ltd. Inhibitors of P38 map kinase
TWI503101B (zh) * 2008-12-15 2015-10-11 波提亞斯數位康健公司 與身體有關的接收器及其方法
KR20110082601A (ko) * 2008-12-19 2011-07-19 피너클 파마수티칼스, 인코포레이티드 페나조피리딘 화합물
CN102596896A (zh) * 2009-06-24 2012-07-18 夏尔有限责任公司 美西律氨基酸和肽前药以及它们的用途
KR20120099462A (ko) 2009-11-12 2012-09-10 더 리젠츠 오브 더 유니버시티 오브 미시건 스피로-옥신돌 ｍｄｍ2 길항제
KR101798128B1 (ko) 2010-02-01 2017-11-16 프로테우스 디지털 헬스, 인코포레이티드 데이터 수집 시스템
CN101906039B (zh) * 2010-06-23 2013-05-08 四川大学华西医院 取代苯酚的羟基酸酯化合物、制备方法及在药物中的应用
MX2010011006A (es) * 2010-10-06 2012-04-18 Senosiain S A De C V Lab Nueva sal de un derivado de pirimidina.
AU2011326395B2 (en) 2010-11-12 2016-01-07 Ascenta Licensing Corporation Spiro-oxindole MDM2 antagonists
US20120196933A1 (en) * 2010-12-23 2012-08-02 Richard Franklin Mexiletine prodrugs
US8629141B2 (en) 2011-05-11 2014-01-14 The Regents Of The University Of Michigan Spiro-oxindole MDM2 antagonists
FR2976944A1 (fr) 2011-06-21 2012-12-28 Centre Nat Rech Scient Prodrogues peptidiques
WO2015112603A1 (en) 2014-01-21 2015-07-30 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
US9303038B2 (en) 2011-09-06 2016-04-05 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological diseases
WO2013064153A1 (en) 2011-10-31 2013-05-10 Claus Selch Larsen Prodrugs of non- steroid anti - inflammatory agents (nsaids)
AU2013202982C1 (en) * 2012-01-06 2017-01-05 Novartis Ag Heterocyclic compounds and methods for their use
CN116898848A (zh) * 2012-01-18 2023-10-20 苏州泰飞尔医药有限公司 治疗肺部疾病的高穿透力前药组合物和医药组合物
CN104379589A (zh) * 2012-05-07 2015-02-25 塞利克斯比奥私人有限公司 抗血小板药剂的前药
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
WO2013168021A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
WO2013167985A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
WO2013167991A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
WO2013168014A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
WO2013168005A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9403857B2 (en) 2012-05-10 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9394288B2 (en) 2012-05-10 2016-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of asthma and allergy
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
AU2013264820A1 (en) 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of mucositis
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
EP2852569B1 (en) 2012-05-23 2020-10-14 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9498461B2 (en) 2012-05-23 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
TWI601725B (zh) * 2012-08-27 2017-10-11 加拓科學公司 取代的氮雜吲哚化合物及其鹽、組合物和用途
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
CN104364231A (zh) 2012-09-08 2015-02-18 塞利克斯比奥私人有限公司 用于治疗炎症和脂质异常的组合物和方法
WO2014151929A1 (en) 2013-03-15 2014-09-25 Proteus Digital Health, Inc. Personal authentication apparatus system and method
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
EP3004049B1 (en) 2013-06-04 2018-09-05 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
WO2015042411A1 (en) 2013-09-20 2015-03-26 Proteus Digital Health, Inc. Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping
US10084880B2 (en) 2013-11-04 2018-09-25 Proteus Digital Health, Inc. Social media networking based on physiologic information
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
NZ724904A (en) 2014-03-14 2023-04-28 Biomolecular Holdings Llc Hybrid immunoglobulin containing non-peptidyl linkage
US10471118B2 (en) 2014-05-30 2019-11-12 Case Western Reserve University Retinylamine derivitives for treatment of ocular disorders
EP3240779B1 (en) 2014-09-26 2020-10-28 Cellixbio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
JP6698643B2 (ja) 2014-09-29 2020-05-27 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ 多発性硬化症の治療のための組成物及び方法
AU2014414316B2 (en) 2014-10-27 2020-04-09 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
CA2973178C (en) 2015-01-06 2022-11-01 Cellix Bio Private Limited Bupivacaine derivatives and their use in the treatment of inflammation and pain
JP6835867B2 (ja) * 2016-03-18 2021-02-24 ケアジェン カンパニー, リミテッドCaregen Co., Ltd. フィナステリドとペプチドの結合体
CN108948139B (zh) * 2017-05-18 2021-10-26 首都医科大学 华法林-4-O-乙酰-Arg-AA化合物,其合成,活性和应用
CN108948140B (zh) * 2017-05-18 2021-10-26 首都医科大学 华法林-4-O-乙酰-Arg-AA十一种化合物,其合成,活性和应用
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
CN111601618A (zh) 2018-09-14 2020-08-28 江阴贝瑞森制药有限公司 孟鲁司特与肽的新缀合物
WO2023190283A1 (ja) * 2022-03-28 2023-10-05 中外製薬株式会社 ポリオキシエチレン構造を含む油性成分を含有する化合物製剤
CN116082439B (zh) * 2023-03-13 2025-08-15 湖北南博生物工程有限公司 一种可用于治疗冠心病的阿司匹林衍生物及其制备方法与应用
CN121652151A (zh) * 2026-02-06 2026-03-13 成都第一制药有限公司 一种莨菪碱衍生物及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650803A (en) * 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
WO1992021341A1 (en) * 1991-05-31 1992-12-10 Pfizer Inc. Use of rapamycin prodrugs as immunosuppressant agents
US5972379A (en) * 1995-02-14 1999-10-26 Sequus Pharmaceuticals, Inc. Liposome composition and method for administering a quinolone
JPH1143467A (ja) * 1997-05-14 1999-02-16 Ikeda Mohandou:Kk 脂肪酸グリセライド誘導体及びグリセライド誘導体、並びにそれらの製造方法
IT1294205B1 (it) * 1997-07-23 1999-03-24 Farmigea Spa Procedimento per la solubilizzazione in acqua e in veicoli acquosi di sostanze farmacologicamente attive
WO2002016395A1 (en) * 2000-08-18 2002-02-28 The Board Of Trustees Of The University Of Illinois Prodrugs of betulinic acid derivatives for the treatment of cancer and hiv
US20020160988A1 (en) * 2001-02-20 2002-10-31 Israel Institute For Biological Research Compounds co-inducing cholinergic up-regulation and inflammation down-regulation and uses thereof
US7045543B2 (en) * 2001-11-05 2006-05-16 Enzrel Inc. Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
ATE396731T1 (de) * 2003-03-25 2008-06-15 Vertex Pharma Thiazole zur verwendung als inhibitoren von protein-kinasen
CN101123878A (zh) * 2003-07-29 2008-02-13 信号研发控股有限责任公司 氨基酸前药

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102924398B (zh) * 2012-11-22 2015-11-18 安徽贝克生物制药有限公司 用于除去依非韦伦对应异构体的方法
CN102924398A (zh) * 2012-11-22 2013-02-13 安徽贝克生物制药有限公司 用于除去依非韦伦对应异构体的方法
CN103880754A (zh) * 2012-12-21 2014-06-25 西藏海思科药业集团股份有限公司 一种丙泊酚碱性氨基酸酯盐
CN103263405A (zh) * 2013-05-08 2013-08-28 南京医科大学 用于治疗糖尿病的药物组合物及其应用
CN103263405B (zh) * 2013-05-08 2015-04-22 南京医科大学 用于治疗糖尿病的药物组合物及其应用
CN103360240A (zh) * 2013-07-23 2013-10-23 西安新通药物研究有限公司 一种高纯度非诺贝酸的制备方法
CN103360240B (zh) * 2013-07-23 2015-03-11 西安新通药物研究有限公司 一种高纯度非诺贝酸的制备方法
CN103951557B (zh) * 2014-04-22 2016-06-08 徐州工业职业技术学院 一种以无机碱为催化剂制备非诺贝特酸的方法
CN103951557A (zh) * 2014-04-22 2014-07-30 徐州工业职业技术学院 一种以无机碱为催化剂制备非诺贝特酸的方法
CN104628554A (zh) * 2015-02-09 2015-05-20 徐州工程学院 一种非诺贝特酸晶型及其制备方法
CN106146444A (zh) * 2015-04-03 2016-11-23 米文君 一种新的化合物及其用途
CN105037180A (zh) * 2015-04-19 2015-11-11 安徽省逸欣铭医药科技有限公司 一种双重作用的中枢性镇痛新化合物、制备方法及用途
CN107949566A (zh) * 2016-05-10 2018-04-20 浙江海正药业股份有限公司 水溶性雷帕霉素类衍生物
WO2017193562A1 (zh) * 2016-05-10 2017-11-16 浙江海正药业股份有限公司 水溶性雷帕霉素类衍生物
US10442835B2 (en) 2016-05-10 2019-10-15 Zhejiang Hisun Pharmaceutical Co., Ltd. Water-soluble rapamycin derivatives
CN107949566B (zh) * 2016-05-10 2021-09-28 浙江海正药业股份有限公司 水溶性雷帕霉素类衍生物
CN106316921A (zh) * 2016-08-19 2017-01-11 河南东泰制药有限公司 一种阿西美辛的制备方法
CN106316921B (zh) * 2016-08-19 2019-03-29 河南东泰制药有限公司 一种阿西美辛的制备方法
CN108299219A (zh) * 2018-02-11 2018-07-20 中国农业大学 O-酰基化丝氨酸衍生物及其制备方法与应用
CN116041259A (zh) * 2023-01-13 2023-05-02 武汉科技大学 一种羟氯喹的衍生物及其制备方法
CN117247327A (zh) * 2023-10-13 2023-12-19 深圳市护家科技有限公司 补骨脂酚衍生物及其盐的制备方法和应用
CN117247327B (zh) * 2023-10-13 2025-09-12 深圳市护家科技有限公司 补骨脂酚衍生物及其盐的制备方法和应用
CN119954651A (zh) * 2023-11-07 2025-05-09 深圳市护家科技有限公司 抗光老化护肤品、耐氧化抗衰老化合物及用途

Also Published As

Publication number Publication date
WO2005046575A2 (en) 2005-05-26
KR20060073584A (ko) 2006-06-28
IL173382A0 (en) 2006-06-11
KR20120116991A (ko) 2012-10-23
CA2534342C (en) 2016-05-10
EP1660017A2 (en) 2006-05-31
WO2005046575A3 (en) 2007-10-04
SG178721A1 (en) 2012-03-29
SG145693A1 (en) 2008-09-29
JP2007510621A (ja) 2007-04-26
AU2004289174A2 (en) 2005-05-26
NZ545570A (en) 2012-07-27
AU2004289174A1 (en) 2005-05-26
CA2534342A1 (en) 2005-05-26
AU2004289174B2 (en) 2011-05-19
ZA200600660B (en) 2007-04-25
EP1660017A4 (en) 2011-03-09
NZ601780A (en) 2012-10-26
NZ601772A (en) 2012-10-26
KR20130081319A (ko) 2013-07-16
JP2013035863A (ja) 2013-02-21

Similar Documents

Publication Publication Date Title
CN101123878A (zh) 氨基酸前药
US8173840B2 (en) Compounds with high therapeutic index
US8563776B2 (en) L-Threonine derivatives of high therapeutic index
US8481483B2 (en) Cyclosporin analogues
CA2913194C (en) Bisulfate of janus kinase (jak) inhibitor and preparation method therefor
US8367053B2 (en) Cyclosporin analogues
US8349312B2 (en) Proline substituted cyclosporin analogues
US8685917B2 (en) Cyclosporin analogues
JP3112327B2 (ja) Ａｃｅの阻害剤として有用な新規なアミノ及びニトロ含有三環式化合物類
EP3915565B1 (en) Xanthine oxidase inhibitor formulations
EP0904284A1 (en) 6-substituted amino-4-oxa-1-azabicyclo (3,2,0) heptan-7-one derivatives as cysteine protease inhibitors
JP2000516257A (ja) タキキニンアンタゴニスト
KR20060101460A (ko) 아미도메틸-치환1-(카르복시알킬)-시클로펜틸카보닐아미노-벤자제핀-ｎ-아세트산 유도체, 그것의 제조를 위한 공정 및 중간체 생성물및 이들 화합물을 포함하는 의약품
CA3134518A1 (en) Arginine gingipain inhibitors
WO2000051640A1 (en) Itchiness-relieving agents and itchiness-relieving effect potentiators
EP1204676B1 (fr) Derives de streptogramines, leur preparation et les compositions qui les contiennent
HK40064899B (en) Xanthine oxidase inhibitor formulations
HK40064899A (en) Xanthine oxidase inhibitor formulations
US20220204457A1 (en) Arginine gingipain inhibitors
JPH0971533A (ja) 凍結乾燥製剤
WO2000042041A1 (en) Carbapenem ester compounds
WO2013123574A1 (en) Orally bioavailable derivatives of d-gamma-glutamyl-d-tryptophan

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20080213